Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving. With several commercial assays available at each stage of the disease, deciding which genomic assays are appropriate for which patients can be nuanced for physicians. In an effort to help guide these decisions in clinical practice, we aim to give an update on the current status of the biomarker field of prostate cancer.
Translational andrology and urology. 2018 Jun [Epub]
Zachary Kornberg, Matthew R Cooperberg, Daniel E Spratt, Felix Y Feng
Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.